Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Axsome Therapeutics Inc AXSM

Healthcare
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.


NDAQ:AXSM - Post by User

Axsome Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(89)
•••
Post by whytestockson Feb 20, 2024 7:15pm
41 Views
Post# 35889892

Neurology-Focused Axsome Therapeutics Reports Deeper Than Ex

Neurology-Focused Axsome Therapeutics Reports Deeper Than Ex
NEWS: $AXSM Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones | BenzingaAxsome Therapeutics Inc&nbsp;(NASDAQ:AXSM) reported fourth-quarter 2023 revenues of $71.53 million, up from $24.37 million a year ago, beating the&...AXSM - Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline Milestones | Benzinga

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities